ALLAKOS INC (ALLK) Stock Fundamental Analysis
NASDAQ:ALLK - Nasdaq - US01671P1003 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to ALLK. ALLK was compared to 572 industry peers in the Biotechnology industry. While ALLK seems to be doing ok healthwise, there are quite some concerns on its profitability. ALLK does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ALLK had negative earnings in the past year.
In the past year ALLK has reported a negative cash flow from operations.
ALLK had negative earnings in each of the past 5 years.
ALLK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -143.65%, ALLK is doing worse than 82.90% of the companies in the same industry.
The Return On Equity of ALLK (-245.72%) is worse than 70.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -143.65% | ||
| ROE | -245.72% | ||
| ROIC | N/A |
ROA(3y)-69.83%
ROA(5y)-49.47%
ROE(3y)-91.22%
ROE(5y)-62.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALLK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ALLK has more shares outstanding
The number of shares outstanding for ALLK has been increased compared to 5 years ago.
There is no outstanding debt for ALLK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ALLK has an Altman-Z score of -17.06. This is a bad value and indicates that ALLK is not financially healthy and even has some risk of bankruptcy.
ALLK's Altman-Z score of -17.06 is on the low side compared to the rest of the industry. ALLK is outperformed by 83.77% of its industry peers.
ALLK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.06 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.08 indicates that ALLK has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.08, ALLK is doing good in the industry, outperforming 63.00% of the companies in the same industry.
A Quick Ratio of 6.08 indicates that ALLK has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.08, ALLK is doing good in the industry, outperforming 63.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.08 | ||
| Quick Ratio | 6.08 |
3. Growth
3.1 Past
The earnings per share for ALLK have decreased by -5.73% in the last year.
EPS 1Y (TTM)-5.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, ALLK will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.01% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.38%
EPS Next 2Y30.96%
EPS Next 3Y23.17%
EPS Next 5Y13.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ALLK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALLK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ALLK's earnings are expected to grow with 23.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.96%
EPS Next 3Y23.17%
5. Dividend
5.1 Amount
No dividends for ALLK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.26
+0.01 (+2.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.4%
Inst Owner Change6.75%
Ins Owners1.39%
Ins Owner Change-5.29%
Market Cap23.23M
Analysts51.67
Price Target0.9 (246.15%)
Short Float %2.73%
Short Ratio0.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.35%
Min EPS beat(2)11.48%
Max EPS beat(2)17.22%
EPS beat(4)2
Avg EPS beat(4)-22.01%
Min EPS beat(4)-69.86%
Max EPS beat(4)17.22%
EPS beat(8)5
Avg EPS beat(8)-8.62%
EPS beat(12)6
Avg EPS beat(12)-12.4%
EPS beat(16)8
Avg EPS beat(16)-10.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.67%
PT rev (3m)-69.44%
EPS NQ rev (1m)-1.18%
EPS NQ rev (3m)11.4%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)1.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.32 | ||
| P/tB | 0.32 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.03
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -143.65% | ||
| ROE | -245.72% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-69.83%
ROA(5y)-49.47%
ROE(3y)-91.22%
ROE(5y)-62.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.63% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.08 | ||
| Quick Ratio | 6.08 | ||
| Altman-Z | -17.06 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)521.85%
Cap/Depr(5y)331.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
EPS Next Y28.38%
EPS Next 2Y30.96%
EPS Next 3Y23.17%
EPS Next 5Y13.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.21%
EBIT Next 3Y18.72%
EBIT Next 5Y26.45%
FCF growth 1Y67.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.7%
OCF growth 3YN/A
OCF growth 5YN/A